Illumina Inc Stock Price, News & Analysis

Illumina, Inc. (NASDAQ: ILMN) announced the investment in seven new genomics startups as part of its fourth global funding cycle for Illumina Accelerator. This brings the portfolio to 68 startups, with 93% of graduates successfully securing additional capital. The new startups focus on diverse areas like therapeutics, diagnostics, and sustainable foods. Applications for the next funding cycle are due by April 1, 2022. Illumina Accelerator offers seed investments, access to advanced tools, and business guidance to help entrepreneurs drive innovation in genomic medicine.

Illumina launched the TruSight™ Oncology Comprehensive (EU), an advanced in vitro diagnostic test designed for cancer patients in Europe. The test analyzes 517 cancer-related genes and various biomarkers, enhancing precision medicine by delivering molecular profiles quickly—within four to five days. This CE-marked kit aligns with European clinical guidelines and allows for streamlined testing in pathology labs. Clinicians can better match therapies to tumor profiles, thus improving patient outcomes. Illumina aims to expand its oncology partnerships, further advancing cancer diagnostics.

Illumina (NASDAQ: ILMN) has appointed Carissa Rollins as Chief Information Officer as of March 14, 2022. With over 30 years of experience, Rollins previously served at UnitedHealthcare, leading technology strategies across various portfolios. CEO Francis deSouza expressed enthusiasm for her role in enhancing IT innovation and customer experiences. Rollins aims to develop high-performance teams to improve IT services and stakeholder experiences, supporting Illumina's mission of personalized medicine.

Illumina (NASDAQ: ILMN) announced its participation in the Cowen Health Care Conference on March 7, 2022. The company's executives will engage in a fireside chat scheduled for 11:50 AM Pacific Time (2:50 PM Eastern Time), which will be accessible via a live webcast on Illumina's website. A replay will be available for at least 30 days post-event. Illumina is a leader in DNA sequencing and related technologies, aiming to enhance human health through genomic innovation.

GRAIL, a healthcare company focused on early cancer detection, has partnered with Point32Health to pilot its Galleri multi-cancer early detection blood test. This initiative marks Point32Health as the first U.S. commercial health plan to collaborate with GRAIL on this innovative test. The pilot will begin with Point32Health employees and later expand to commercial members, aiming to gather real-world evidence on its effectiveness. Galleri can detect over 50 cancer types with a low false positive rate, potentially saving lives by enabling earlier treatment.

Illumina reported Q4 2021 revenue of $1,198 million, marking a 26% increase year-over-year. GAAP net income was $112 million or $0.71 per diluted share, down from $257 million or $1.75 the previous year. For fiscal 2021, total revenue reached $4,526 million, up 40% from $3,239 million in 2020. However, cash flow from operations fell to $545 million from $1,080 million in the prior year. The company expects consolidated revenue growth between 14% to 16% for 2022 and GAAP earnings per share of $3.04 to $3.24.

Illumina (NASDAQ: ILMN) announced its participation in two upcoming investor conferences. The SVB Leerink 2022 Global Healthcare Conference will feature a fireside chat on February 17, 2022, at 9:00 AM PT. The Citi 2022 Healthcare Conference will follow with another chat on February 24, 2022, at 9:30 AM PT. Both events will be accessible via live webcast through Illumina's website, with replays available for at least 30 days afterward. Illumina continues to lead in DNA sequencing technology, enhancing global health.

Illumina has formed a partnership with the Jean Perrin Center at Clermont-Ferrand University Hospital in France to evaluate comprehensive genomic profiling (CGP) in late-stage cancer patients. This collaboration will utilize data from the CELIA study to compare CGP effectiveness against standard care approaches, including small panel tests. The TruSight™ Oncology 500 assay will be employed to analyze genetic mutations in various cancer types, aiming to enhance precision oncology practices. The study seeks to solidify CGP's role in French healthcare and ultimately improve patient outcomes.

Illumina (NASDAQ: ILMN) has partnered with the National Cancer Center Japan for a research project focused on nasopharyngeal carcinoma, particularly prevalent in Asia. This study, part of the A-TRAIN initiative, aims to analyze blood-based genomic profiles of affected patients, contributing to personalized treatment development. Nasopharyngeal carcinoma has significant incidence rates in Southeast Asia, representing a critical area for new therapeutic strategies. The research involves up to 96 patients using Illumina's TruSight Oncology 500 ctDNA, highlighting regional collaboration for cancer treatment advancements.